Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial

IMPORTANCE: Some patients with migraine, particularly those in primary care, require effective, well-tolerated, migraine-specific oral preventive treatments. OBJECTIVE: To examine the efficacy of atogepant, an oral, small-molecule, calcitonin gene–related peptide receptor antagonist, using 4 levels...

Descripción completa

Detalles Bibliográficos
Autores principales: Lipton, Richard B., Pozo-Rosich, Patricia, Blumenfeld, Andrew M., Dodick, David W., McAllister, Peter, Li, Ye, Lu, Kaifeng, Dabruzzo, Brett, Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle, Trugman, Joel M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2022
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178435/
https://www.ncbi.nlm.nih.gov/pubmed/35675076
http://dx.doi.org/10.1001/jamanetworkopen.2022.15499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178435/
https://www.ncbi.nlm.nih.gov/pubmed/35675076
http://dx.doi.org/10.1001/jamanetworkopen.2022.15499

Ejemplares similares